Moreover, recent research shows that fibrosis progression in MASLD is influenced by gut microbiota dysbiosis and genetic variants, such as PNPLA3, which, along with the TLR4 and IL17 SNPs, contribute to the advancement of fibrogenesis [10]. This evidence concerns the gene IL17A and metabolic dysfunction-associated steatotic liver disease.